U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07012642) titled 'Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema' on June 01.
Brief Summary: Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby address...